APONTIS PHARMA AG sets placement price for its IPO at EUR 19.00 per share
APONTIS PHARMA AG / Key word(s): IPO
NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THE PRESS RELEASE.
Publication of inside information pursuant to Article 17 of the Regulation (EU) No. 596/2014
Monheim am Rhein, 06 May 2021. APONTIS PHARMA AG ("APONTIS PHARMA" or "Company") has set the placement price for its initial public offering ("IPO") at EUR 19.00 per share.
In total, 5,290,000 ordinary bearer shares with no par value were placed with investors in the IPO. The placement comprises 2,000,000 new shares from a capital increase against cash contributions, 1,600,000 secondary shares in a base deal and 1,000,000 secondary shares from the exercise of an upsize option by the major shareholder Paragon Partners as well as 690,000 secondary shares provided by Paragon Partners in connection with an over-allotment option, corresponding to a total placement volume of EUR 101 million.
Based on the placement price, APONTIS PHARMA's market capitalization amounts to EUR 162 million post-money. Upon completion of the IPO and assuming full exercise of the greenshoe option, the expected free float will amount to 62%, which will allow for liquid trading of the Company's shares.
The existing shareholders Paragon Partners and APONTIS PHARMA'S Management will continue to hold 31% and 7%, respectively, of the Company's shares following the placement.
The first day of trading of APONTIS PHARMA's shares on the Frankfurt Stock Exchange (Scale) is scheduled for 11 May 2021 under the international securities identification number (ISIN) DE000A3CMGM5 and the ticker symbol APPH. Settlement with delivery of shares is expected to take place on 12 May 2021.
These materials may not be, directly or indirectly, published, distributed or transmitted in or into the United States, Canada, Australia or Japan or any other jurisdiction in which the distribution or release would be unlawful. These materials do not constitute an offer of securities for sale or a solicitation of an offer to purchase securities (the "Securities") of Apontis Pharma AG (the "Company") in the United States, Australia, Canada, Japan or any other jurisdiction in which such offer or solicitation is unlawful. The Securities of the Company may not be offered or sold in the United States absent registration or an exemption from registration under the U.S. Securities Act of 1933, as amended (the "Securities Act"). There will be no public offering of the securities in the United States. The Securities of the Company have not been, and will not be, registered under the Securities Act. The securities referred to herein may not be offered or sold in Australia, Canada or Japan or to, or for the account or benefit of, any national, resident or citizen of Australia, Canada or Japan subject to certain exceptions.
In the United Kingdom, this document is only being distributed to and is only directed at persons who (i) are investment professionals falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the "Order"), or (ii) are persons falling within Article 49(2)(a) to (d) of the Order (high net worth companies, unincorporated associations, etc.), or (iii) to whom an invitation or inducement to engage in an investment activity (within the meaning of section 21 of the United Kingdom Financial Services and Markets Act 2000) in connection with the issue or sale of any securities may otherwise be lawfully communicated or caused to be communicated (all such persons together being referred to as "Relevant Persons"). This document is directed only at Relevant Persons and must not be acted on or relied on by persons who are not Relevant Persons. Any investment or investment activity to which this document relates is available only to Relevant Persons and will be engaged in only with Relevant Persons.
This publication constitutes neither an offer to sell nor a solicitation to buy securities of APONTIS PHARMA AG. The offer is being made solely by the means of, and on the basis of, the published securities prospectus (including any supplements thereto, if any). An investment decision regarding the publicly offered securities of APONTIS PHARMA AG should only be made on the basis of the securities prospectus. The securities prospectus is available free of charge on the APONTIS PHARMA AG website.
06-May-2021 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
|Company:||APONTIS PHARMA AG|
|Listed:||Regulated Unofficial Market in Frankfurt (Scale)|
|EQS News ID:||1193654|
|End of Announcement||DGAP News Service|